Larsen, Mogens Lytken

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 8,961

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)

Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal

Health Promotion and Cardiovascular PreventionClinical practice guidelines implementation

Cited by 8,490

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 4,854

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases

Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal

Peripheral Artery Disease ManagementVascular Procedures and Complications

Cited by 1,506

High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk

van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., et al. (2008) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 374

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease

Faergeman, O., Holme, I., Fayyad, R., Bhatia, S., Grundy, S. M., Kastelein, J. J. P., LaRosa, J. C., Larsen, M. L., Lindahl, C., Olsson, A. G., et al. (2009) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 154